Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

Posts Tagged ‘heart failure’

Unemployment associated with 50% higher risk of death in heart failure patients

Posted by fidest press agency su martedì, 2 Mag 2017

infarto-miocardico-acutoParis, France. Unemployment is associated with a 50% higher risk of death in patients with heart failure, according to research presented today at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure. The observational study in more than 20 000 heart failure patients found that not being employed was linked with a greater likelihood of death than history of diabetes or stroke.“The ability to hold a job brings valuable information on wellbeing and performance status,” said lead author Dr Rasmus Roerth, a physician at Copenhagen University Hospital, Denmark. “And workforce exclusion has been associated with increased risk of depression, mental health problems and even suicide.”“In younger patients with heart failure, employment status could be a potential predictor of morbidity and mortality,” he continued. “If that was the case, employment status could help to risk stratify young heart failure patients and identify those needing more intensive rehabilitation.”This study compared the risks of all-cause death and recurrent heart failure hospitalisation in patients with heart failure, according to whether they were employed at baseline or not. Using the unique personal identification number assigned to all residents in Denmark, individual data was linked from nationwide registries on hospitalisation, prescribed medication, education level, public welfare payments, and death.The study included all patients of working age (18 to 60 years) with a first hospitalisation for heart failure in Denmark between 1997 and 2012. Of the 21 455 patients with a first hospitalisation for heart failure, 11 880 (55%) were part of the workforce at baseline.During an average follow-up of 1005 days, 16% of employed and 31% of unemployed patients died, while 40% of employed and 42% of unemployed patients were rehospitalised for heart failure.After adjusting for age, sex, education level and comorbidities, heart failure patients unemployed at baseline had a 50% increased risk of death and 12% increased risk of rehospitalisation for heart failure compared to those who were employed. Not being part of the workforce was associated with a higher likelihood of death than history of diabetes or stroke.Dr Roerth said: “We found that heart failure patients out of the workforce at baseline had a higher risk of death. Not being part of the workforce was associated with a risk of death comparable to that of having diabetes or stroke. Those without a job also had an increased risk of recurrent heart failure hospitalisation.”Dr Roerth said the exact mechanism on how employment status may affect mortality is complex and most likely multifactorial. “The ability to work can be seen as a measure of performance status and be interpreted as whether patients meet the physical requirements of a full time job or not,” he said.But he added: “Employment status is more than just a physical measurement as it also has an influence on quality of life, and has been shown to be important for mental health and wellbeing. Thus, both from a physical and psychological point of view it makes sense to include employment status in the evaluation of young heart failure patients’ prognosis.”Dr Roerth said it was perhaps not surprising that employment status has importance for prognosis. “But the observation that employment status is associated with an increased risk of death comparable to that of many other comorbidities such as diabetes and stroke is notable,” he said.In terms of implications of the findings, Dr Roerth said workforce exclusion could be used to identify heart failure patients at risk of poor outcomes and that efforts to get patients back into work might be beneficial.He said: “It could be highly valuable to assess employment status and actually think of workforce exclusion as a prognostic marker in line with suffering from serious chronic diseases. Knowledge on why workforce exclusion has happened for the individual patient might lead to ideas on how it can be prevented – for example with more intensive rehabilitation, physical activity, psychological treatment, or a different job.” Authors: ESC Press Office.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

A Brescia un congresso internazionale sullo scompenso cardiaco

Posted by fidest press agency su martedì, 30 agosto 2016

ospedale bresciaItaliani, europei, americani e giapponesi: è davvero internazionale e prestigioso il gruppo di relatori riuniti a Brescia giovedì 1 e venerdì 2 settembre 2016 per partecipare al congresso “Heart Failure – Drug development at the crossroad”, dedicato allo scompenso cardiaco.
Lo scompenso cardiaco è una condizione per la quale il cuore non è più in grado di pompare sangue in misura sufficiente a soddisfare le richieste dell’organismo.
Oltre i 65 anni lo scompenso cardiaco rappresenta la prima causa di ricovero in ospedale; anche per questo è considerato un problema di salute pubblica di enorme rilievo. A soffrire di scompenso cardiaco in Italia sono circa 600.000 persone e si stima che la sua frequenza raddoppi a ogni decade di età (dopo i 65 anni arriva al 10% circa).
Lo scompenso cardiaco è spesso l’evoluzione finale comune a molte malattie e fattori di rischio cardiovascolari, tra le quali infarto, ipertensione, diabete e malattie cardiache.
Il congresso è organizzato dell’Università degli Studi di Brescia e promosso dalla Fondazione Internazionale Menarini. Responsabile scientifico del congresso è Savina Nodari, Cattedra e Unità Operativa di Cardiologia Università degli Studi di Brescia, ASST Spedali Civili di Brescia.
Il congresso si svolge all’Università degli studi di Brescia, Facoltà di Medicina e Chirurgia, Aula Magna, Viale Europa 11. E’ aperto ai medici, è gratuito e assegna crediti formativi.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Increased risk of dead for heart failure patients with each nhs hospital admission

Posted by fidest press agency su lunedì, 29 agosto 2016

cardilogy congressRome, Italy Heart failure patients have a 2% increased risk of dying with each admission to NHS hospitals, according to research presented at ESC Congress 2016 today.1 The 15 year study in more than 450 000 patients from the ACALM Study Unit, Birmingham, UK included 13 416 patients with heart failure.“Heart failure accounts for over one million inpatient bed days, 2% of National Health Service (NHS) in-hospital work load and 5% of all emergency medical admissions to hospital in the UK,” said lead author Dr Rahul Potluri, founder of the ACALM (Algorithm for Comorbidities, Associations, Length of stay and Mortality) Study Unit.
Worryingly, hospital admissions for patients with heart failure are projected to rise by 50% over the next 25 years. In Europe, previous studies have indicated that more than a quarter of patients with heart failure have been readmitted to hospital as soon as three months after previous discharge and more than 10% of them died.The current study included 457 233 patients above the age of 18 years who had been admitted to hospitals in the West Midlands, UK, from 2000 to 2014. Of these, 13 416 patients had been diagnosed with heart failure. For each patient, the investigators calculated the number of readmissions to hospital within five years and recorded if they had died during that period.The research showed that each hospital admission was associated with a 2% increased risk of death. Heart failure patients who had 4 to 7 admissions to hospital over the study period had an almost 20% increased risk of dying compared to those with 1 to 3 admissions to hospital.“We have a triple whammy because heart failure is increasing, hospitalisation is increasing and this study shows that the risk of heart failure patients dying with each admission is higher by 2%,” said Dr Potluri. “The findings reflect the fact that heart failure is a progressive disease and should be a challenge to physicians to improve care even more.”He continued: “Every effort should be made to start and/or optimise heart failure medications before patients leave hospital and ensure other interventions such as multidisciplinary community support are available for heart failure patients to reduce the risk of admission to hospital.” Dr Paul Carter, co-author, said: “We need to diagnose heart failure patients efficiently and ensure that they are taking appropriate heart failure medications prior to discharge from hospital so that we minimise the chances of readmission as much as possible. At the moment, there is significant variation in how well this is done across hospitals in spite of numerous clinical guidelines.”

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

ESC Guidelines on acute and chronic heart failure launched today

Posted by fidest press agency su sabato, 21 Mag 2016

laserflorenceFlorence, Italy – 21 May 2016: European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure are published today in European Heart Journal1 and the European Journal of Heart Failure, and presented at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure. Around 1–2% of adults in developed countries have heart failure. At 55 years of age, the lifetime risk is 33% for men and 28% for women. During one year, 17% of hospitalised and 7% of stable/ambulatory heart failure patients will die, primarily from sudden death and worsening heart failure.The 2016 guidelines include LCZ696 for this first time. This drug is the first in the class of angiotensin receptor neprilysin inhibitors (ARNIs) and was shown in the PARADIGM-HF trial to be superior to the angiotensin-converting enzyme inhibitor (ACEI) enalapril for reducing the risk of death and hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF) who met strict inclusion and exclusion criteria. Professor Piotr Ponikowski, Chairperson of the guidelines Task Force, said: “The issue of how to include LCZ696 in the treatment algorithm generated a lot of discussion. We recommend that the drug should replace ACEIs in patients who fit the PARADIGM-HF criteria. The Task Force agreed that more data is needed before it can be recommended in a broader group of patients.”
Professor Adriaan A. Voors, Task Force Co-Chairperson, said: “Used in the right patients, LCZ696 will have a positive effect on prognosis. Adoption of LCZ696 may however be a challenge because patients and doctors are usually reluctant to change a drug they have used for decades. The cost of the swap will be relatively small compared to the new cancer drugs that extend life for just a few months.”A new category of heart failure with mid-range ejection fraction (HFmrEF) has been added for patients with a left ventricular ejection fraction (LVEF) ranging from 40 to 49%. It sits between HFrEF, defined as LVEF less than 40%, and heart failure with preserved ejection fraction (HFpEF), defined as LVEF above 50%. Professor Ponikowski said: “There are no evidence based treatments for patients with LVEF 40% or above. Many patients fall into the mid-range category and this should stimulate research into novel therapies.”
Cardiac resynchronisation therapy (CRT) is now contraindicated in patients with a QRS duration less than 130 msec after the EchoCRT study found it may increase mortality in this group. This is a change from the 120 msec cut-off in the 2012 guidelines. The indications for CRT vary according to the presence or absence of left bundle branch block and QRS duration.The concept of ‘time is muscle’ in acute heart failure, adopted from acute coronary syndrome, is included in the guidelines for the first time and demands urgent diagnosis and treatment.2 “Acute heart failure is a life-threatening condition and earlier appropriate treatment may prevent organ damage,” said Professor Voors.A new algorithm is introduced for the diagnosis of heart failure in the non-acute setting and is based on the evaluation of heart failure probability. “This algorithm will be more useful in clinical practice for general practitioners and other non-cardiologists faced with patients who may have heart failure,” said Professor Ponikowski. “It clearly defines when heart failure can be ruled out and when further tests are needed.” Adaptive servo-ventilation (ASV) is not recommended in patients with HFrEF and central sleep apnoea after mortality increased in the SERVE-HF trial. Professor Ponikowski said: “We took for granted that ASV benefitted these patients. The trial was a big surprise and ASV is now contraindicated in this situation.”Novel recommendations to prevent or delay the onset of heart failure and prolong life include: treatment of hypertension, statins for patients with or at high risk of coronary artery disease, and empagliflozin (a sodium-glucose cotransporter 2, or SGLT2, inhibitor) for patients with type 2 diabetes.Professor Voors said: “We have better ways to treat comorbidities that increase the risk of heart failure. Several drugs for diabetes were associated with a higher risk of deterioration of heart failure but now we have an SGLT2 inhibitor that reduces the risk of heart failure hospitalisations in high risk patients, although studies with SGLT2 inhibitors in patients with established heart failure are still lacking.”Professor Ponikowski concluded: “Heart failure is becoming a preventable and treatable disease. Implementing the guidelines published today will give patients the best chance of a positive outcome.”

Posted in Cronaca/News, Lettere al direttore/Letters to the publisher | Contrassegnato da tag: , , | Leave a Comment »

New heart failure guidelines set to be launched at congress in May

Posted by fidest press agency su giovedì, 28 aprile 2016

Sophia AntipolisSophia Antipolis. New European Society of Cardiology (ESC) heart failure guidelines are set to be launched at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure in Florence, Italy. The world’s leading heart failure congress is the main annual meeting of the Heart Failure Association (HFA) of the ESC. It takes place 21 to 24 May in the historic sixteenth century Fortezza da Basso. Professor Gerasimos Filippatos, HFA president, said: “Journalists at the congress will be the first to hear the latest clinical advice in the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, which will be revealed on day one of the congress. Subsequent sessions are devoted to specific aspects of the guidelines including acute heart failure, co-morbidities, arrhythmias and devices, and chronic heart failure – providing plenty of material for stories.” Highly anticipated late breaking science will be presented in three sessions and feature state of the art discoveries from clinical trials, registries and basic science studies. More than 2 000 abstracts and clinical cases were submitted for presentation which is a new record and promises top quality research and news for the press. A highlights session will summarise the best findings of the abstract programme, selected and presented by experts. The full scientific programme is available here. This year’s event is expected to host more delegates than ever before, with 5 000 set to attend. The event attracts numerous professions, including cardiologists, basic scientists, cardiac nurses, intensivists, anaesthesiologists, and emergency room physicians. Members of the press should register now.The successful World Congress on Acute Heart Failure returns this year with debates, abstracts, and late breaking trials. Professor Filippatos said: “This is the place for the media to hear cutting edge developments in the cardiologiafast moving area of acute heart failure.”A novel session will see three clinical cases enacted in virtual patients created for the congress. Experts will guide the audience through these challenging cases and share their feedback and take-home messages. During four days packed with science there will be more than 100 scientific sessions and contributions from over 300 international leaders in the field. Industry representatives will present innovations and discuss products in the pipeline. The basic and translational science programme has been enhanced with nine pre-arranged sessions with renowned experts plus breakthrough abstract presentations. A local track features six sessions in Italian and English and is organised in collaboration with societies and experts from Italy. During the inaugural session, Karl Swedberg will give the Eugene Braunwald lecture on the success of neurohormonal and heart rate control in the treatment of heart failure. Luigi Tavazzi will give the Philip Poole Wilson lecture on new scenarios in medical science during the young investigator award session on basic and translational science. A new HFA Career Cafe will be held on Saturday morning giving young heart failure specialists, who have applied ahead of the congress, the chance to receive face to face career advice and recommendations from three world renowned experts. The congress theme is “Heart Failure: State of the Art” and reflects the launch of the new guidelines. Recommendations on the diagnosis and management of acute and chronic heart failure with drugs and devices, all based on the most up to date evidence, will be presented and discussed for the first time. Professor Filippatos said: “Sign up now to get the latest on hot topics in acute and chronic heart failure at the biggest international meeting in the specialty.” Also don’t miss the first public presentation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Be the first to know what the Task Force says by attending the session dedicated to this topic on Tuesday 24 May.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Procoralan® Receives European Approval for Use in Heart Failure

Posted by fidest press agency su mercoledì, 15 febbraio 2012

Paris.(PRNewswir) Approval brings promise of better prognosis and improved quality of life for millions of chronic heart failure patients in EuropeServier today announced that the company’s heart rate lowering agent, Procoralan® (ivabradine), the first selective If channel inhibitor, has been approved by the European Commission for the treatment of patients with chronic heart failure. The European Commission’s decision to authorise this new indication for Procoralan followed the review of data from the SHIfT trial, the largest-ever morbi-mortality study of treatments for chronic heart failure involving more than 6000 patients. It demonstrated that the treatment significantly reduced the risk of death and hospitalisation from heart failure, and improved the quality of life of people living with the disease.[2,3] This reduction in mortality was highly significant in patients with a heart rate of 75 beats per minute (bpm), or above, for whom Procoralan is now indicated.Professor Michel Komajda, Co-Chairman of the SHIFT Executive Committee commented: “The decision to authorise this new indication for Procoralan is good news for doctors and patients, and is a significant step forward in the treatment of heart failure. While ACE inhibitors and beta-blockers remain the main stay in the treatment of heart failure, the results of the SHIfT trial demonstrate that a reduction in heart rate when elevated with Procoralan improves clinical outcomes and symptoms, prevents disease progression, and has beneficial effect on daily activities and the quality of life of heart failure patients”.
Chronic heart failure affects 15 million patients in Europe (2% to 3% of the overall population).[4] It is a disabling condition and, despite improvements in treatment and management, generally has a poor prognosis. Heart failure impairs the heart’s ability to pump effectively and to maintain sufficient circulation to meet the body’s needs.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Impulse Dynamics Inc.

Posted by fidest press agency su lunedì, 20 aprile 2009

Orangeburg, N.Y., IMPULSE Dynamics, manufacturer of the OPTIMIZER System for patients with heart failure, announced that it has recently closed a new round of financing of $40MM USD from institutional and private investors that will provide the necessary capital for realizing its strategic plans.  The OPTIMIZER System, which is CE marked, is commercially available in parts of Europe and Asia and is being investigated in the United States, and delivers cardiac contractility modulating (CCM) signals that are intended to improve the strength of heart muscle contraction. IMPULSE Dynamics recently released the findings of its 428 patient one year study of the OPTIMIZER System conducted in the U.S. Heart failure is a disease that affects more than 22 million people around the world, many of which have no treatment options.
IMPULSE Dynamics, with offices in U.S., Switzerland and Israel, is a pioneering medical device company focused on the development and commercialization of the OPTIMIZER System, an implantable device for the treatment of medically refractory heart failure. Additional information can be found at

Posted in Economia/Economy/finance/business/technology, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »